Ascendis Pharma A/S – American Depositary Shares (NASDAQ:ASND) Stock Is Shorted More

November 10, 2018 - By Richard Conner

The stock of Ascendis Pharma A/S – American Depositary Shares (NASDAQ:ASND) registered an increase of 18.19% in short interest. ASND’s total short interest was 343,100 shares in November as published by FINRA. Its up 18.19% from 290,300 shares, reported previously. With 116,300 shares average volume, it will take short sellers 3 days to cover their ASND’s short positions. The short interest to Ascendis Pharma A/S – American Depositary Shares’s float is 1.57%.

The stock decreased 0.81% or $0.52 during the last trading session, reaching $63.38. About 60,085 shares traded. Ascendis Pharma A/S (NASDAQ:ASND) has risen 123.84% since November 10, 2017 and is uptrending. It has outperformed by 108.22% the S&P500.

Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies to treat unmet medical needs. The company has market cap of $2.65 billion. It is developing TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; and TransCon Treprostinil that is in Phase I clinical trial for the treatment of pulmonary arterial hypertension, a life-threatening disease characterized by elevated blood pressure in the pulmonary arteries. It currently has negative earnings. The firm is also developing TransCon Peptides for the treatment of diabetes; TransCon ranibizumab, a compound to support injection of ranibizumab in ophthalmology; TransCon parathyroid hormone for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia.

Ascendis Pharma A/S (NASDAQ:ASND) Ratings Coverage

Among 5 analysts covering Ascendis Pharma (NASDAQ:ASND), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Ascendis Pharma has $85 highest and $7000 lowest target. $77.40’s average target is 22.12% above currents $63.38 stock price. Ascendis Pharma had 6 analyst reports since May 14, 2018 according to SRatingsIntel. The firm has “Buy” rating given on Thursday, August 30 by Stifel Nicolaus. The firm has “Hold” rating given on Thursday, May 31 by Leerink Swann. The stock of Ascendis Pharma A/S (NASDAQ:ASND) has “Buy” rating given on Tuesday, May 15 by Wedbush. The firm has “Buy” rating by J.P. Morgan given on Monday, May 14.

More notable recent Ascendis Pharma A/S (NASDAQ:ASND) news were published by: Nasdaq.com which released: “Ascendis Pharma A/S Announces Upcoming Investor Presentations” on November 02, 2018, also Streetinsider.com with their article: “UPDATE: Credit Suisse Starts Ascendis Pharma (ASND) at Outperform” published on November 09, 2018, Nasdaq.com published: “Market Trends Toward New Normal in Ascendis Pharma A/S, Diodes, Laureate Education, Randgold Resources …” on October 26, 2018. More interesting news about Ascendis Pharma A/S (NASDAQ:ASND) were released by: Benzinga.com and their article: “The Daily Biotech Pulse: SITC Presentations Pick Up Pace, Sandoz’ Voluntary Recall” published on November 09, 2018 as well as Nasdaq.com‘s news article titled: “Ascendis Pharma Announces Formation of VISEN Pharmaceuticals to Develop and Commercialize TransCon …” with publication date: November 08, 2018.

Ascendis Pharma A/S (NASDAQ:ASND) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>